Breath holding spell. Other abnormalities of breathing
Conditions
Interventions
Intervention 1: Intervention group: Levetiracetam: For 3 months, they are treated with Levetiracetam (100 mg/ml) with a dose of 40 mg/kg/day. Changes in the number of attacks and the percentage of con
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Months to 6 Years
Inclusion criteria
Inclusion criteria: Patients with severe breath holding attacks at least 3 times a month Aged less than 6 years and more than 6 months Normal growth and development Normal cardiovascular, cerebral and neurological examinations Not having electrolyte disturbances, hypoglycemia and iron deficiency Not having any seizure or neurological problem or epilepsy
Exclusion criteria
Exclusion criteria: Inability to follow up occurrence of any drug reaction or any other problem during treatment occurrence of seizure or any neurological disorders during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of breath holding spells. Timepoint: Before the intervention and monthly up to 3 months. Method of measurement: Questionnaire.;Severity of breath holding spells: Percentage of convulsive attacks. Timepoint: Before the intervention and monthly up to 3 months. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| EEG pattern. Timepoint: Before the intervention and 3 months later. Method of measurement: Electroencephalography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad reza Ghazavi
Esfahan University of Medical Sciences
Outcome results
None listed